Journal article

Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax (TM) polysaccharide adjuvant

David L Gordon, Dimitar Sajkov, Richard J Woodman, Yoshikazu Honda-Okubo, Manon MJ Cox, Susanne Heinzel, Nikolai Petrovsky

Vaccine | ELSEVIER SCI LTD | Published : 2012

University of Melbourne Researchers

Grants

Awarded by National Institutes of Health, National Institute of Allergy and Infectious Diseases


Awarded by National Institutes of Health


Funding Acknowledgements

We thank Dr. Nancy Cox (Centers for Disease Control and Prevention, Atlanta, GA) and Dr. Jesse Goodman (US Food and Drug Administration, Rockville, MD) for the expedited availability of the novel H1N1 virus strain. We thank the clinical trial coordinators and research staff including Sharen Pringle, Brigit McAteer, Kylie Bragg, Lynda Borg, Susan Virgin, Lyndall Stone, Frances Kissajukian and Melody Vrakking for their expert assistance. We thank all the study participants for their voluntary participation in the study. Reference ferret sera to H1N1/A/California/07/2009 was provided by the Biodefense and Emerging Infections (BEI) Research Resources Repository, NIH. Development of Advax (TM) adjuvant was supported by Contracts U01-AI061142 and HHSN272200800039 C from the National Institutes of Health, National Institute of Allergy and Infectious Diseases. This publication's contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health, National Institute of Allergy and Infectious Diseases.This work was supported by National Institutes of Health [Contracts AI061142 and HHSN272200800039C].